熱門資訊> 正文
Lisata Therapeutics在终止出售给Kuva Labs后暴跌
2026-07-25 00:59
- Lisata Therapeutics (LSTA) sank 16% after its planned sale to Kuva Labs was terminated
- The termination comes after Kuva Labs was unable to obtain sufficient financing to fund its takeover offer, according to an 8-K on Friday.
- As a result of the termination, Kuva is obligated under the merger agreement to pay Lisata (LSTA) a termination fee of $2 million.
- Lisata (LSTA) announced in January that it had entered into a binding term sheet with privately held Kuva Labs under which Kuva plans to acquire the company through a tender offer priced at $4.00 per share in cash.
More on Lisata Therapeutics
- Seeking Alpha’s Quant Rating on Lisata Therapeutics
- Historical earnings data for Lisata Therapeutics
- Financial information for Lisata Therapeutics
推薦文章
銀色債券2026今起認購！保底息率4.25釐，每手3年累計派息至少1,275港元
華盛早報 | 貝森特兩日救市！美債回購規模或超40億美元；Anthropic衝擊史上最大IPO；恆指季檢結果，中際旭創、長飛光纖財報今日公佈
美股前瞻 | 史詩級「軋空」來襲！比特幣升破7.2萬美元；業績股齊遇冷！沃爾瑪盤前大跌逾6%，阿里、網易均跌近4%
一圖看懂 | AI與雲業務表現強勁！阿里Q1營收2690億元，同比增9%略超預期；阿里雲外部商業化收入加速增至45%
一圖看懂 | 泡泡瑪特上半年營收171億、淨利50億均大遜預期！星星人IP逆勢暴漲580%；王寧稱計劃半年內大額回購20-50億
Moderna暴漲177%！mRNA癌症疫苗迎來「ChatGPT時刻」？16只港美標的誰會接過下一棒？
「影子股」已暴漲90%！如何在Anthropic史上最大IPO前搶跑入局？最全攻略來了
港股異動 | 全球首個mRNA癌症疫苗三期成功落地！港股醫藥股齊衝高，康希諾生物飆升49%，雲頂新耀勁升42%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
